Pathological transition as the arising mechanism for drug resistance in lung cancer

• Main Authors: Yueqing Chen, Waiying Yvonne Tang, Xinyuan Tong, Hongbin Ji
• Format: Article
• Language: English
• Published: Wiley 2019-10-01
• Series: Cancer Communications
• Subjects: Lung cancer; Drug resistance; Pathological transition
• Online Access: http://link.springer.com/article/10.1186/s40880-019-0402-8

Abstract Despite the tremendous efforts for improving therapeutics of lung cancer patients, its prognosis remains disappointing. This can be largely attributed to the lack of comprehensive understanding of drug resistance leading to insufficient development of effective therapeutics in clinic. Based on the current progresses of lung cancer research, we classify drug resistance mechanisms into three different levels: molecular, cellular and pathological level. All these three levels have significantly contributed to the acquisition and evolution of drug resistance in clinic. Our understanding on drug resistance mechanisms has begun to change the way of clinical practice and improve patient prognosis. In this review, we focus on discussing the pathological changes linking to drug resistance as this has been largely overlooked in the past decades.